Caption Management’s Akebia Therapeutics AKBA Stock Holding History

Caption Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-24,692	Closed	-$34.3K	–	1615
2026 Q1	$34.3K	Hold	24,692	–	–	﹤0.01%	1435
2025 Q4	$39.8K	Buy	+24,692	New	+$51.7K	﹤0.01%	1475
2022 Q1	–	Sell	-210,000	Closed	-$449K	–	1425
2021 Q4	$475K	Buy	+210,000	New	+$573K	0.01%	1258
2020 Q3	–	Sell	-50,000	Closed	-$678K	–	1005
2020 Q2	$678K	Buy	50,000 +10,000	+25%	+$103K	0.02%	624
2020 Q1	$303K	Sell	40,000 -50,531	-56%	-$393K	0.02%	637
2019 Q4	$572K	Buy	90,531 +17,031	+23%	+$80.9K	0.02%	607
2019 Q3	$288K	Hold	73,500	–	–	0.02%	557
2019 Q2	$356K	Buy	73,500 +67,500	+1,125%	+$384K	0.02%	516
2019 Q1	$49K	Buy	+6,000	New	+$41.2K	﹤0.01%	536

Other funds holding AKBA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Caption Management's AKBA Position: Q2 2026 in Review

Caption Management sold out of Akebia Therapeutics (AKBA) in Q2 2026, closing a stake of 24,692 shares — an estimated $34.3K sold.

Caption Management first reported a position in AKBA in Q1 2019 and held it in 9 quarters. The position peaked at $678K in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

Caption Management reported no remaining Akebia Therapeutics position as of Q2 2026 after selling out during the quarter.
Caption Management sold 24,692 Akebia Therapeutics shares in Q2 2026, an estimated $34.3K.
Caption Management first reported a position in Akebia Therapeutics in Q1 2019 and held it in 9 quarters.
Caption Management's Akebia Therapeutics position peaked at $678K in Q2 2020.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.